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Abstract
Background: HO-1 participates in the degradation of heme. Its products can exert unique
cytoprotective effects. Numerous tumors express high levels of HO-1 indicating that this enzyme
might be a potential therapeutic target. In this study we decided to evaluate potential cytostatic/
cytotoxic effects of zinc protoporphyrin IX (Zn(II)PPIX), a selective HO-1 inhibitor and to evaluate
its antitumor activity in combination with chemotherapeutics.
Methods: Cytostatic/cytotoxic effects of Zn(II)PPIX were evaluated with crystal violet staining and
clonogenic assay. Western blotting was used for the evaluation of protein expression. Flow
cytometry was used to evaluate the influence of Zn(II)PPIX on the induction of apoptosis and
generation of reactive oxygen species. Knock-down of HO-1 expression was achieved with siRNA.
Antitumor effects of Zn(II)PPIX alone or in combination with chemotherapeutics were measured
in transplantation tumor models.
Results: Zn(II)PPIX induced significant accumulation of reactive oxygen species in tumor cells. This
effect was partly reversed by administration of exogenous bilirubin. Moreover, Zn(II)PPIX exerted
potent cytostatic/cytotoxic effects against human and murine tumor cell lines. Despite a significant
time and dose-dependent decrease in cyclin D expression in Zn(II)PPIX-treated cells no
accumulation of tumor cells in G1 phase of the cell cycle was observed. However, incubation of C-
26 cells with Zn(II)PPIX increased the percentage of cells in sub-G1 phase of the cells cycle. Flow
cytometry studies with propidium iodide and annexin V staining as well as detection of cleaved
caspase 3 by Western blotting revealed that Zn(II)PPIX can induce apoptosis of tumor cells. B16F10
melanoma cells overexpressing HO-1 and transplanted into syngeneic mice were resistant to either
Zn(II)PPIX or antitumor effects of cisplatin. Zn(II)PPIX was unable to potentiate antitumor effects
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potentiated toxicity of 5-FU and cisplatin.
Conclusion: Inhibition of HO-1 exerts antitumor effects but should not be used to potentiate
antitumor effects of cancer chemotherapeutics unless procedures of selective tumor targeting of
HO-1 inhibitors are developed.
Background
Heme oxygenase (HO) is a microsomal enzyme that cata-
lyzes oxidative cleavage of the porphyrin ring in heme
molecule leading to the formation of biliverdin, carbon
monoxide (CO) and free iron [1,2]. Biliverdin is further
converted into bilirubin by biliverdin reductase. All HO
products exert pleiotropic effects including numerous
cytoprotective responses [3]. Bilirubin and biliverdin are
among the most potent endogenous scavengers of reactive
oxygen species (ROS) [4]. CO exerts strong antiapoptotic
and anti-inflammatory effects through induction of solu-
ble guanylyl cyclase. It suppresses production of tumor
necrosis factor (TNF), interleukin-1β (IL-1β) and CCL4
chemokine (macrophage inflammatory protein-1β), but
up-regulates synthesis of anti-inflammatory IL-10 [5].
Finally, free iron (Fe2+) despite participation in Fenton
reaction that leads to formation of highly reactive
hydroxyl radicals, also activates Fe-ATPase, a transporter
that removes intracellular iron, as well as induces expres-
sion of ferritin heavy chains which sequester free iron and
exert specific cytoprotective roles [6].
Two isoforms of heme oxygenase exist. HO-1 is an induc-
ible enzyme that belongs to the heat shock protein
(HSP32) family. Its expression is induced by a vast array
of stress-inducing stimuli that include: oxidative stress,
heat shock, UV irradiation, exposure to heavy metals and
numerous other toxins, including chemotherapeutics [7].
Some observations indicate that HO-1 and its products
also exert anti-inflammatory effects and participate in the
control of growth and proliferation of tumor cells. Ele-
vated constitutive levels of HO-1 have been observed in a
number of human tumors including glioma, melanoma,
prostate, pancreatic and renal cell carcinoma, lymphosar-
comas, Kaposi sarcoma and hepatoma [7]. Enhanced
expression of HO-1 can also contribute to tumor progres-
sion through promotion of angiogenesis and metastases
formation [8,9]. Furthermore, the increased basal level of
HO-1 expression in tumor cells can be further elevated by
chemotherapeutics, radiotherapy or photodynamic ther-
apy [10,11].
Altogether HO products participate in attenuation of oxi-
dative stress, suppression of inflammatory responses,
inhibition of apoptosis and promotion of angiogenesis
[12,13]. Therefore, accumulating evidence indicates that
HO-1 can be a therapeutic target for antitumor treatment.
Indeed, it was shown that zinc protoporphyrin IX
(Zn(II)PPIX) or its pegylated derivative, a potent HO
inhibitor, can exert significant antitumor effects against
several tumors in mice [14-16]. Moreover, inhibition of
HO-1 expression or activity was shown to increase respon-
siveness of tumor cells to other anticancer treatments in
vitro [10,16,17]. The aim of these studies was to explore
the in vivo role of HO-1 in tumor growth and in protecting
tumor cells against chemotherapeutics.
Methods
Tumor cells
Human ovarian carcinoma (MDAH2774), human pan-
creatic adenocarcinoma (Mia PaCa2), human breast carci-
noma (MDA-MB231), murine breast carcinoma (EMT6)
cell lines were purchased from ATCC (Manassas, VA,
USA). Murine colon-26 (C-26), a poorly differentiated
colon adenocarcinoma cell line was obtained from prof.
Danuta Dus (Institute of Immunology and Experimental
Medicine, Wroclaw, Poland). B16F10 murine melanoma
cells were provided by Dr. M. Kubin (Wistar Institute,
Philadelphia, PA). Cells were cultured in RPMI 1640
medium (C-26 and B16F10) (Invitrogen, Carlsbad, CA,
USA) or DMEM (MDAH2774, Mia PaCa2, MDA-MB231
and EMT6) supplemented with 10% heat-inactivated fetal
calf serum, antibiotics, 2-mercaptoethanol (50 μM) and
L-glutamine (2 mM) (all from Invitrogen), hereafter
referred to as culture medium.
Reagents
Zinc (II) propoporphyrin IX (Zn(II)PPIX), a HO-1 inhib-
itor, was purchased from Frontier Scientific Europe Ltd.
(Carnforth, Lancashire, United Kingdom) and was dis-
solved in dimethylsulfoxide (DMSO) (Sigma, St. Louis,
USA) to the final stock concentration of 5 mM. Bilirubin
(Sigma, St Louis, MO, USA) was dissolved in 0.1 N NaOH
to the final stock concentration of 10 mM. Hemin (from
Sigma) was dissolved in 0.1 N KOH to the final stock con-
centration of 10 mM. All the solutions were prepared in
the dark right before adding to the cell cultures.
Mice
Female BALB/c and C57Bl/6 mice, 8–12 weeks of age were
used for in vivo experiments. Breeding pairs were obtained
from the Institute of Oncology (Warsaw, Poland). Mice
were kept in conventional conditions with full access to
food and water during experiments. All of the animalPage 2 of 12
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approved by the Ethical Committee of the Medical Uni-
versity of Warsaw.
Western blotting
For Western blotting C-26 were treated with Zn(II)PPIX
for 24, 48 or 72 h. After indicated times of culture cells
were washed with PBS and lysed with radioimmunopre-
cipitation assay buffer (RIPA) containing Tris base 50
mM, NaCl 150 mM, NP-40 1%, sodium deoxycholate
0.25% and EDTA 1 mM supplemented with Complete®
protease inhibitor cocktail tablets (Roche Diagnostics,
Mannheim, Germany). Protein concentration was meas-
ured using Bio-Rad Protein Assay (BioRad, Hercules, CA,
USA). Equal amounts of whole cell proteins were sepa-
rated on 12% SDS-polyacrylamide gel, transferred onto
Protran® nitrocellulose membranes (Schleicher and
Schuell BioScience Inc., Keene, NH, USA), blocked with
TBST [Tris buffered saline (pH 7.4) and 0.05% Tween 20]
supplemented with 5% nonfat milk and 5% FBS. The fol-
lowing antibodies at 1:1000 dilution were used for the 24
h incubation: mouse monoclonal anti-α-tubulin
(Promega Corporation, Madison, WI, USA), rabbit poly-
clonal anti-cleaved caspase 3 (Cell Signaling Technology,
Beverly, MA, USA) and mouse monoclonal anti-cyclin D1
(Santa Cruz). After extensive washing with TBST, the
membranes were incubated for 45 min with correspond-
ing alkaline phosphatase-coupled secondary antibodies
(from Jackson Immuno Research). The color reaction for
alkaline phosphatase was developed using nitroblue tetra-
zolium and 5-bromo-4-chloro-3-indolyl phosphate
(Sigma).
Cytostatic/cytotoxic assay
The cytostatic and/or cytotoxic effects were measured
using crystal violet staining as described [18]. Briefly,
tumor cells were dispensed into 96-well plates (Sarstedt,
Numbrecht, Germany) at a concentration of 5 × 103 cells
per well and allowed to attach overnight. The following
day investigated agents were added at indicated concen-
trations. Cells were kept in dark for 48 or 72 h. After the
incubation time the cells were rinsed with PBS and stained
with 0.5% crystal violet in 2% ethanol for 10 min at room
temperature. Plates were washed four times with tap water
and the cells were lysed with 1% SDS solution. Absorb-
ance was measured at 595 nm using an enzyme-linked
immunosorbent assay reader (SLT Labinstrument GmbH,
Salzburg, Austria), equipped with a 595 nm filter. Cyto-
toxicity was expressed as relative viability of tumor cells
(% of control cultures incubated with medium only) and
was calculated as follows: relative viability = (Ae - Ab) ×
100/(Ac - Ab), where Ab is the background absorbance, Ae
is experimental absorbance, and Ac is the absorbance of
untreated controls.
Clonogenic assay
MDAH2774 or Mia PaCa2 cells were plated at 2.5 × 105
cells per 35-mm dish (Sarstedt). Four hours after seeding,
Zn(II)PPIX was added at indicated concentrations. After
24 hours of incubation in dark, the cells were washed with
PBS, trypsinized and seeded into 35-well plates in triplets
at the concentration of 1 × 103 cells per a dish. Fresh
medium containing Zn(II)PPIX was added. The medium
was removed daily for the 6 following days. After 14 day
incubation in the dark, the cells were rinsed with PBS,
fixed for 10 min in pure methanol and stained with 0.5%
crystal violet in 2% ethanol for 10 min at room tempera-
ture. Then the plates were washed four times with tap
water and air-dried. The images of the plates were made
using the Olympus Camedia C750 Ultra Zoom digital
camera.
FACS analysis of cell cycle and apoptosis
For the cell cycle analysis, C-26 cells were seeded into 6-
well plates (Sarstedt) at the concentrations 1 to 3 × 105
cells per well and incubated in dark with 2.5 μM or 5 μM
Zn(II)PPIX. The incubation time varied from 24 to 72 h.
After the incubation, the cells were washed with PBS,
trypsinized and centrifuged at 1000 rpm for 10 min in
4°C. The pellet was resuspended in 0.5 ml of PBS and
injected under the surface of ice cold 70% ethanol for 24-
h fixation in -20°C. At the day of analysis, the cells were
washed from ethanol, stained with 5 μg/ml propidium
iodide (PI, Becton Dickinson, Mountain View, CA, USA)
at the presence of RNase A (Becton Dickinson) for 30 min
at 37°C. For the analysis of apoptosis induction C-26 or
Mia PaCa2 cells were seeded into 6-well plates (Sarstedt)
at the concentrations 1 to 3 × 105 cells per well and incu-
bated in dark with 2.5 μM or 5 μM Zn(II)PPIX. The incu-
bation time varied from 6 to 72 h. After the incubation,
the cells were washed with PBS, trypsinized and centri-
fuged at 1000 rpm for 10 min in 4°C. The pellet was resus-
pended in 0.5 ml of Annexin-binding buffer (BioSource
International, Camarillo, CA, USA) and then incubated
for 15 min with 5 μl of Annexin V-FITC (BioSource).
Finally, the cells were stained with 5 μg/ml PI. The
cytofluorometric analysis was performed using FACSCali-
bur (Becton Dickinson). For single analysis 1 × 104 cells
were used. Data were collected at the wavelength of 580
nm (for PI) and 520 nm for FITC, and analysed with CEL-
LQuest 1.2 software (Becton Dickinson).
HO-1 RNAi
Small interfering RNA against murine HO-1 was obtained
by chemical synthesis from Dharmacon (Lafayette, CO,
USA). The following sequence was used for targeting of
murine HO-1: 5'-GCA-GAA-CCC-AGU-CUA-UGC-C-3'.
For RNAi experiments 3,5 × 105 C-26 cells were seeded
into 6-well plates (Sarstedt). After 24 h cells were washed
with Optimem™ medium (Invitrogen) and transfectedPage 3 of 12
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the manufacturer's protocol. 10 μM hemin was added to
the appropriate groups 2 h befor RNAi procedure. After 8
h trasfection medium was replaced with full DMEM cul-
ture medium. 24 h after transfection cells were harvested
and ROS generation analysis was performed (see below).
ROS generation assay
For determination of ROS generation, C-26 cells (3,5 ×
105 cells per well) were seeded into 6-well paltes
(Sarstedt) and treated for 24 h with 2.5 μM Zn(II)PPIX
and/or 50 μM biliubin or subjected to HO-1 RNAi (as
described above). On the day of the analysis, cells were
trypsynized, washed 3 times in ice-cold PBS and resus-
pended in 1 ml of PBS. One μl of CM-H2DCFDA (Invitro-
gen, 5 mM DMSO solution) was added to each sample for
20 min incubation at 37°C. Then, cells were washed twice
with ice-cold PBS and subjected to flow cytometry using
FACSCalibur (Becton Dickinson). For single analysis 1 ×
104 cells were used. Data were collected at the wavelength
of 520 nm and analysed with CELLQuest 1.2 software
(Becton Dickinson).
Tumor treatment and monitoring
For assessment of antitumor activity of Zn(II)PPIX in vivo,
exponentially growing C-26 were harvested, re-suspended
in PBS medium to the appropriate concentration, and
injected at the dose of 1 × 105 cells per mouse into the
footpad of the right hind limb of experimental mice.
Tumor cell viability measured by trypan blue exclusion
was always above 95%. For in vivo treatment Zn(II)PPIX
was dissolved in DMSO and further diluted in 0.9% NaCl
to required concentrations. Final DMSO concentration
was always less then 0.1%. Zn(II)PPIX was distributed
intraperitoneally at doses from 12.5 to 50 mg per kg of
body weight or orally at doses from 11 to 22 mg per kg of
body weight. Control animals received 0.1% DMSO solu-
tion in 0.9% NaCl i.p. or orally.
For in vivo experiments evaluating the effectiveness of
combine treatment using Zn(II)PPIX and chemothera-
peutics, exponentially growing C-26, EMT6 and B16F10
cells were injected at the dose of 1 × 105, 1 × 105 and 1 ×
106 cells per mouse, respectively into the footpad of the
right hind limb of experimental mice. Zn(II)PPIX treat-
ment (50 mg/kg i.p.) was started on the day 7 after inocu-
lation of tumor cells and continued for 7 consecutive
days. First dose of HO-1 inhibitor was administered 1 h
before each of the chemotherapeutics to eliminate any
possible interactions (such as neutralization) between
drugs. Cisplatin (Platidam, Pliva-Lachema, Cech Repub-
lic) at the dose of 7.5 mg/kg i.p., 5-FU (Fluorouracil 1000
Medac, Medac, Hamburg, Germany) – 50 mg/kg i.p., or
doxorubicin (Adriblastina RD, Pharmacia Italia, Milan,
Italy) – 7.5 mg/kg i.p. were administered at a single dose
on the day 7th after inoculation of tumor cells.
For in vivo experiments determining influence of HO-1
gene transfer on sensitivity of B16F10 melanoma cells to
cisplatin treatment, exponentially growing B1 (HO-1
transfected) and B5E (empty plasmid transfected) cells
were injected at the dose of 1 × 106 cells per mouse into
the footpad of the right hind limb of experimental mice.
Cisplatin (Platidam, Pliva-Lachema) was administered
i.p. at a single dose (2.5, 5.0 or 7.5 mg/kg) on the day 7th
after inoculation of tumor cells.
For in vivo experiments exponentially growing B1 and B5E
cells were injected at a dose of 1 × 106 cells per mouse into
the footpad of the right hind limb of experimental mice.
Cisplatin was administered i.p. at a single dose of 7.5 mg/
kg on the 7th day after inoculation of tumor cells.
Zn(II)PPIX treatment (50 mg/kg i.p.) was started on the
day 7 after inoculation of tumor cells and continued for 7
consecutive days. First dose of HO-1 inhibitor was admin-
istered 1 h before the chemotherapeutic.
In all the experiments mentioned above, local tumor
growth was determined every second day as described pre-
viously [19] by the formula: tumor volume (mm3) =
(longer diameter) × (shorter diameter)2.
Statistical analysis
Data were calculated using Microsoft™ Excel 2003. Differ-
ences in in vitro cytotoxicity assays and tumor volume
were analyzed for significance by Student's t test. Signifi-
cance was defined as a two-sided P < 0.03.
Results
Zn(II)PPIX induces potent cytostatic/cytotoxic effects 
against murine and human tumor cells
Four different cell lines of murine (C-26, colon adenocar-
cinoma) and human (Mia PaCa2, a pancreatic cancer,
MDAH2774, ovarian carcinoma, and MDA-MB231,
breast carcinoma) origin were incubated with increasing
concentrations of Zn(II)PPIX for 48 and/or 72 hours. HO-
1 inhibitor exerted dose- and time-dependent cytostatic/
cytotoxic effects as measured with crystal violet staining
(Fig. 1). Similar effects were observed in MTT assay (not
shown) and in a clonogenic assay performed with Mia
PaCa2 and MDAH2774 cells (Fig. 2).
To get insight into the mechanism of cytostatic/cytotoxic
effects induced by Zn(II)PPIX cell cycle analysis and
induction of apoptosis were performed. Incubation of C-
26 cells with Zn(II)PPIX for 48 or 72 h resulted in dose-
and time-dependent reduction of cells in G1 phase of the
cell cycle (Fig. 3A). This effect correlated with decreased
cyclin D1 expression (Fig. 3B) and increased percentage ofPage 4 of 12
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annexin V staining of C-26 cells incubated with 5 μM
Zn(II)PPIX for 24–72 h indicated that the sub-G1 fraction
of cells might represent apoptotic cells (Fig. 3C). The frac-
tion of late apoptotic and necrotic cells increased from
10.9% in controls to 30.4% after 72 h incubation with
Zn(II)PPIX. Western blotting analysis indicated that a 48-
h incubation of C-26 cells leads to accumulation of
cleaved (active) caspase-3 (Fig. 3D).
An influence of Zn(II)PPIX as well as knock-down of HO-
1 expression with siRNA were used to get insight into the
specificity of the Zn(II)PPIX-mediated effects. As shown
in Fig. 3E siRNA against a murine HO-1 (moHO-1 siRNA)
was effective in reducing the expression level of HO-1 in
murine C-26 cells. A siRNA against a human gene (huHO-
1 siRNA) was ineffective (Fig. 3E) as well as an irrelevant
siRNA against enhanced green fluorescent protein (eGFP,
not shown). Inhibition of HO-1 activity with Zn(II)PPIX
resulted in increased ROS generation in C-26 cells (Fig.
3F). Similar effects were observed when HO-1 expression
was knocked-down with a specific siRNA against HO-1
(Fig. 3G). The influence of Zn(II)PPIX on ROS formation
was completely abrogated when C-26 were co-incubated
with 50 μM bilirubin (Fig. 3F). Similarly, the influence of
siRNA was significantly decreased by forced expression of
HO-1 by pre-incubation of C-26 with 10 μM hemin (Fig.
3G).
Zn(II)PPIX induces antitumor effects in a murine C-26 
model
BALB/c mice inoculated with C-26 cells were treated with
Zn(II)PPIX for 7 consecutive days. HO-1 inhibitor was
administered either intraperitoneally (i.p.) or per os and
the tumor volume was monitored every second day, start-
ing from day 7 after inoculation of tumor cells.
Zn(II)PPIX exerts cystostatic/cytotoxic effects against tumor cellsFigure 1
Zn(II)PPIX exerts cystostatic/cytotoxic effects against tumor cells. Tumor cells were incubated with serial dilutions 
of Zn(II)PPIX for 48 or 72 hours. The cytostatic and/or cytotoxic effects of treatment were measured with a standard crystal 
violet staining assay. Bars represent means ± SD. *P < 0.05 (two way Student's t-test) in comparison with controls.Page 5 of 12
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manifested by the retardation of tumor growth. A statisti-
cal significance was reached on days 17 and 19 for
Zn(II)PPIX administered at a dose of 25 mg/kg either i.p.
or orally (Fig. 4A and 4B). A stronger effect was observed
when Zn(II)PPIX was administered i.p. at a dose of 50
mg/kg, where a statistically significant retardation of
tumor growth was observed on days 13–19, as compared
with controls (Fig. 4A).
The influence of Zn(II)PPIX on formation of tumor cell coloniesFigure 2
The influence of Zn(II)PPIX on formation of tumor cell colonies. For the clonogenic assay, MDAH2774 or Mia PaCa2 
cells were plated at a concentration of 1 × 103 cells/dish. Medium containing Zn(II)PPIX was replaced daily for 1–6 consecutive 
days. On day 14 after PDT, the plates were fixed with methanol and stained with crystal violet.Page 6 of 12
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Zn(II)PPIX induces apoptosis and increases formation of reactive oxygen speciesFigure 3
Zn(II)PPIX induces apoptosis and increases formation of reactive oxygen species. C-26 cells were grown in Petri 
dishes for 24 hours before addition of Zn(II)PPIX for the indicated time. [A] Cell cycle analysis was performed by flow cytom-
etry analysis using ethanol-fixed, propidium iodide-stained cells. [B and D] Western blotting for expression of cyclin D1, 
cleaved caspase 3 or tubulin as a loading control was performed. [C] Induction of apoptosis was evaluated by staining of cells 
with propidium iodide and annexin V. [E] HO-1 silencing was evaluated with Western blotting. Controls represent expression 
of HO-1 in hemin-treated C-26 cells. HuHO-1 siRNA is a negative control targeting xenogeneic (human) HO-1 gene, muHO-
1 siRNA is a murine sequence that knocks-down HO-1 expression in C-26 cells. [F and G] production of reactive oxygen spe-
cies was evaluated with flow cytometry by measuring CM-H2DCFDA fluorescence in comparison with controls.
BMC Cancer 2008, 8:197 http://www.biomedcentral.com/1471-2407/8/197Overexpression of HO-1 in B16F10 cells confers resistance 
to cisplatin treatment
B16F10 cells were transfected with HO-1 gene (B1 clones)
or an empty control plasmid (B5E cells). Tumor cells were
inoculated with mixtures of clones and their response to
cisplatin treatment was investigated. Cisplatin was admin-
istered i.p. at three doses of 2.5, 5.0 or 7.5 mg/kg and the
tumor growth was monitored every second day. While in
control B5E tumors cisplatin administration led to a sig-
nificant retardation of tumor growth, the B1 tumors were
completely resistant to the chemotherapeutic (Fig. 5A and
5B). Administration of 50 mg/kg Zn(II)PIX alone pro-
duced significant retardation of tumor growth only in B5E
tumor model (Fig. 5D), but was completely ineffective in
B1 tumors (Fig. 5C). Furthermore, it did not restore cispl-
atin sensitivity in B1 tumors (Fig. 5C).
Zn(II)PPIX does not affect antitumor effects of 
chemotherapeutics
In further studies the influence of Zn(II)PPIX (50 mg/kg)
on the in vivo antitumor effects of chemotherapeutics was
evaluated. Three different cell lines syngeneic with BALB/
c or C57Bl/6 mice were used, namely C-26, B16F10
melanoma and EMT6 breast adenocarcinoma. The fol-
lowing chemotherapeutics were used in these studies: 5-
fluorouracil at a dose of 50 mg/kg (5-FU, for C-26), cispl-
atin at a dose of 5 mg/kg (for B16F10) and doxorubicin at
a dose of 7,5 mg/kg (for EMT6 cells). Although in in vivo
studies administration of Zn(II)PPIX (at a dose of 50 mg/
kg) resulted in retardation of tumor growth (although in
EMT6 tumors the effect was only modest) there was no
further potentiation of the antitumor effects by concomi-
tant administration of Zn(II)PPIX together with chemo-
therapeutics (Fig. 6A–C). Only for Zn(II)PPIX and 5-FU a
slightly stronger effect was observed for the combination
treatment, but the difference between the combination
and single drug-treated tumors did not reach statistical
significance (Fig. 5A). Remarkably, the combined admin-
istration of Zn(II)PPIX with either cisplatin or 5-FU
resulted in significant weight loss (Fig. 6D and 6E). This
effects was not observed in mice treated with Zn(II)PPIX
and doxorubicin (Fig. 6F). No treatment-related mortality
was observed in these experiments.
Discussion
The role of HO-1 in tumor development is still not com-
pletely elucidated and some recent reports demonstrate
discordant or even completely opposite results. Neverthe-
less, accumulating evidence indicates that HO-1 is
expressed or overexpressed by a large variety of human
tumors and that it plays a critical role in progression of
neoplastic diseases [7]. For example, it was shown that
Zn(II)PPIX exerts antitumor effects against C-26 adencarcinomas in miceFigure 4
Zn(II)PPIX exerts antitumor effects against C-26 adencarcinomas in mice. BALB/c mice were inoculated with 1 × 
105 of C-26 cells. On day 7 after inoculation of tumor cells mice were treated with Zn(II)PPIX administered i.p. or p.o. for 7 
consecutive days [A and B]. Graphs show the influence of the treatment on the growth of C-26 tumors in mice. *P < 0.05 (two 
way Student's t-test) in comparison with controls.Page 8 of 12
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proliferation rate of various tumor cells [7,10,15,20],
although opposite effects are observed in breast cancer
cells [21]. Specific siRNA-mediated down-regulation of
HO-1 resulted in suppression of proliferation of pancre-
atic cancer cells [10] or in induction of apoptosis of lung
cancer cells [17]. Similarly, cytostatic/cytotoxic effects
were observed with HO-1 inhibitors, such as Zn(II)PPIX
[15,22] or its pegylated derivative (PEG-ZnPP) [16].
Moreover, overexpression of HO-1 increased viability,
Antitumor effect of cisplatin or the combined treatment with Zn(II)PPIX and/or cisplatin in mice transplanted with control or HO-1 over xpressing B16F10 tumorsFigure 5
Antitumor effect of cisplatin or the combined treatment with Zn(II)PPIX and/or cisplatin in mice transplanted 
with control or HO-1 overexpressing B16F10 tumors. C57Bl/6 mice were inoculated with 1 × 106 of HO-1 overex-
pressing (B1) or mock-transfected (B5E) cells. On day 7 after inoculation of tumor cells mice were treated with cisplatin at a 
dose of 2.5, 5.0 or 7.5 mg/kg administered i.p. [A and B] or with cisplatin (5 mg/kg in a single i.p. injection) and 50 mg/kg of 
Zn(II)PPIX administered i.p. for 7 consecutive days [C and D]. Graphs show the influence of the treatment on the growth of 
melanoma in mice. *P < 0.05 (two way Student's t-test) in comparison with controls.Page 9 of 12
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Mice inoculated with HO-1 overexpressing melanomas
fared worse than controls, had a higher number of metas-
tases and a significantly shortened survival [9].
The results of present experiments performed with addi-
tional cell lines further establish that Zn(II)PPIX is an
active agent capable of inducing cytostatic and cytotoxic
effects against a number of human and mouse tumor cell
lines. Moreover, in two different tumor models
Zn(II)PPIX was demonstrated to exert potent antitumor
effects manifested by the retardation of tumor growth.
Development of effective antitumor regimens requires
administration of drugs in combination. The role of the
combination treatment is to target different pathways in
tumor cells in order to elicit more robust antitumor
response. Synergistic antitumor effects might lead to
decreased dosing and elimination or a significant attenu-
ation of toxic side effects of drugs used in monotherapy.
Several previous reports demonstrated that HO-1, which
is frequently over-expressed in tumor cells, might partici-
pate in tumor-protective effects against a number of
chemotherapeutics, radiotherapy and photodynamic
therapy [10,11]. By targeting HO-1 it might be possible to
sensitize tumor cells to more effective cytotoxic effects of
other therapeutic regimens. Indeed, in vitro data seem to
support this idea. HO-1 knock-down sensitized pancreatic
cancer cells to gemcitabine [10] and lung cancer cells to
cisplatin [17]. Moreover, PEG-ZnPP sensitized colon can-
cer cells to cytostatic/cytotoxic effects of camptothecin or
doxorubicin [16]. However, the efficacy of combining
chemotherapeutics with HO-1 inhibitor in vivo has not yet
been addressed.
Antitumor effect of the combined treatment with Zn(II)PPIX and/or chemotherapeuticsFigure 6
Antitumor effect of the combined treatment with Zn(II)PPIX and/or chemotherapeutics. Mice were inoculated 
with 1 × 105 of C-26 or EMT6 cells or with 1 × 106 of B16F10 cells. On day 7 after inoculation of tumor cells mice received a 
single dose of chemotherapeutics: 50 mg/kg of 5-FU [A, D], 5 mg/kg of cisplatin [B, E] or 7.5 mg/kg of doxorubicin [C, F]. 
Zn(II)PPIX was administered i.p. for 7 consecutive days at a dose of 50 mg/kg [A-F]. Graphs show the influence of the treat-
ment on the growth of tumors in mice [A-C] or on the change in mice weight as compared with initial weight. *P < 0.05 (two 
way Student's t-test) in comparison all other groups.Page 10 of 12
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with other antitumor agents it must be kept in mind that
HO-1 and its products affect multiple signaling and met-
abolic pathways and play an important role in protection
of normal cells against multiple environmental insults.
For example, HO-1 protects retinal cells against light-
induced damage [23], ameliorates ischemia-reperfusion
injury elicited by a number of different conditions [24],
inhibits endothelial cell apoptosis induced by endoplas-
mic reticulum stress [25], protects mice from apoptotic
liver damage [26], prevents development of atherosclero-
sis in LDL-receptor knock-out mice [27], improves sur-
vival of transplanted organs [28] or prevents development
of gastric ulcers in rats [29]. HO-1 also protects normal
cells and tissues against toxic effects of chemotherapeu-
tics. Heme-induced HO-1 expression protects against
cyclophosphamide-mediated hemorrhagic cystitis [30],
HO-1 attenuates cisplatin-induced toxicity in renal tubu-
lar cells [31] or in auditory cells [32], it also decreases dox-
orubicin-mediated cardiotoxicity [33]. Moreover,
transgenic mice deficient in HO-1 (-/-), develop more
severe renal failure and have significantly greater renal
injury compared with wild-type (+/+) mice treated with
cisplatin [34].
At doses used in the studies presented here Zn(II)PPIX
was unable to restore cisplatin sensitivity in HO-1 overex-
pressing melanoma cells nor was it capable of potentiat-
ing antitumor effects of cisplatin, doxorubicin or 5-FU in
three different models. Nonetheless, Zn(II)PPIX signifi-
cantly potentiated toxicity of cisplatin and 5-FU as deter-
mined by decreased weight loss. Tozer et al, have shown
that administration of Zn(II)PPIX at a dose of 45 μmoles/
kg is ineffective in inhibiting HO-1 activity in tumors [35].
The dose used in these studies (50 mg/kg) corresponds to
almost 80 μmoles/kg/mouse. Although it was not meas-
ured whether Zn(II)PPIX used at this dose and at this
administration schedule was capable of inhibiting HO-1
activity it can be concluded that it is ineffective in neither
inducing antitumor effects in HO-1-overexpressing
B16F10 melanomas nor in restoring sensitivity to cispla-
tin. Future studies should address an important, and not
addressed in these studies, question of drug administra-
tion schedule. Specifically, what should be the timing of
Zn(II)PPIX administration in combination with chemo-
therapeutics to effectively inhibit HO-1 activity in tumor
cells? Is it possible to design combination strategies that
would target HO-1 in tumors and not in normal tissues?
It seems that the influence of Zn(II)PPIX administration
on the activity of HO-1 in tumor versus normal tissues
will be of utmost importance in designing combination
treatments.
Conclusion
Altogether, these studies show that despite promising
cytostatic/cytotoxic and even antitumor effects elicited by
Zn(II)PPIX, this HO-1 inhibitor should not be used in
combination with chemotherapeutics. It can be hypothe-
sized however, that selective and efficient delivery of HO-
1 inhibitors to the tumor might prove to be a more
rational approach for combination therapies with chemo-
therapeutics. Indeed, as demonstrated by Fang et al. [16]
and Iyer at al. [36] it is possible to prepare Zn(II)PIX deriv-
atives with a higher tumor selectivity. It remains to be elu-
cidated whether these strategies are more effective and less
toxic.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
DN participated in experimental design, performed most
of in vitro and in vivo experiments and participated in the
writing of the manuscript, MB participated in in vivo
experiments, MW and JB did most of the flow cytometry
studies, AS measured ROS formation in tumor cells, PS
participated in cytostatic/cytotoxic asssays in vitro, TI par-
ticipated in in vivo experiments, HW prepared control and
HO-1 overexpressing B16F10 melanoma cells, AJ partici-
pated in experimental design, JD participated in experi-
mental design and participated in the writing of the
manuscript, TS participated in experimental design and in
in vitro experiments, and participated in manuscript cor-
rection, JG conceived the study, participated in its design
and coordination and wrote the first draft of the manu-
script. All authors read and approved the manuscript.
Acknowledgements
Supported by grant PBZ KBN 107/P04/2004 from Ministry of Science and 
Higher Education. Alicja Jozkowicz is the International Senior Research Fel-
low of Wellcome Trust. We would like to thank Elzbieta Gutowska and 
Anna Czerepinska for excellent technical assistance. Tadeusz Issat and 
Magdalena Winiarska are recipients of the START stipend from the Foun-
dation for Polish Science.
References
1. Ryter SW, Alam J, Choi AM: Heme oxygenase-1/carbon monox-
ide: from basic science to therapeutic applications.  Physiol Rev
2006, 86:583-650.
2. Dulak J, Deshane J, Jozkowicz A, Agarwal A: Heme oxygenase-1
and carbon monoxide in vascular pathobiology: focus on ang-
iogenesis.  Circulation 2008, 117:231-241.
3. Takahashi T, Shimizu H, Morimatsu H, Inoue K, Akagi R, Morita K,
Sassa S: Heme oxygenase-1: a fundamental guardian against
oxidative tissue injuries in acute inflammation.  Mini Rev Med
Chem 2007, 7:745-753.
4. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN:
Bilirubin is an antioxidant of possible physiological impor-
tance.  Science 1987, 235:1043-1046.
5. Otterbein LE, Bach FH, Alam J, Soares M, Tao Lu H, Wysk M, Davis
RJ, Flavell RA, Choi AM: Carbon monoxide has anti-inflamma-
tory effects involving the mitogen-activated protein kinase
pathway.  Nature Med 2000, 6:422-428.Page 11 of 12
(page number not for citation purposes)
BMC Cancer 2008, 8:197 http://www.biomedcentral.com/1471-2407/8/1976. Crichton RR, Wilmet S, Legssyer R, Ward RJ: Molecular and cellu-
lar mechanisms of iron homeostasis and toxicity in mamma-
lian cells.  J Inorg Biochem 2002, 91:9-18.
7. Jozkowicz A, Was H, Dulak J: Heme oxygenase-1 in tumors: is it
a false friend?  Antioxid Redox Signal 2007, 9(12):2099-2117.
8. Sunamura M, Duda DG, Ghattas MH, Lozonschi L, Motoi F, Yamauchi
J, Matsuno S, Shibahara S, Abraham NG: Heme oxygenase-1 accel-
erates tumor angiogenesis of human pancreatic cancer.  Ang-
iogenesis 2003, 6:15-24.
9. Was H, Cichon T, Smolarczyk R, Rudnicka D, Stopa M, Chevalier C,
Leger JJ, Lackowska B, Grochot A, Bojkowska K, et al.: Overexpres-
sion of heme oxygenase-1 in murine melanoma: increased
proliferation and viability of tumor cells, decreased survival
of mice.  Am J Pathol 2006, 169:2181-2198.
10. Berberat PO, Dambrauskas Z, Gulbinas A, Giese T, Giese N, Kunzli
B, Autschbach F, Meuer S, Buchler MW, Friess H: Inhibition of
heme oxygenase-1 increases responsiveness of pancreatic
cancer cells to anticancer treatment.  Clin Cancer Res 2005,
11:3790-3798.
11. Nowis D, Legat M, Grzela T, Niderla J, Wilczek E, Wilczynski GM,
Glodkowska E, Mrowka P, Issat T, Dulak J, et al.: Heme oxygenase-
1 protects tumor cells against photodynamic therapy-medi-
ated cytotoxicity.  Oncogene 2006, 25:3365-3374.
12. Loboda A, Jazwa A, Wegiel B, Jozkowicz A, Dulak J: Heme oxygen-
ase-1-dependent and -independent regulation of angiogenic
genes expression: effect of cobalt protoporphyrin and cobalt
chloride on VEGF and IL-8 synthesis in human microvascular
endothelial cells.  Cell Mol Biol (Noisy-le-grand) 2005, 51(4):347-355.
13. Deshane J, Chen S, Caballero S, Grochot-Przeczek A, Was H, Li Calzi
S, Lach R, Hock TD, Chen B, Hill-Kapturczak N, et al.: Stromal cell-
derived factor 1 promotes angiogenesis via a heme oxygen-
ase 1-dependent mechanism.  J Exp Med 2007, 204:605-618.
14. Fang J, Sawa T, Akaike T, Akuta T, Sahoo SK, Khaled G, Hamada A,
Maeda H: In vivo antitumor activity of pegylated zinc pro-
toporphyrin: targeted inhibition of heme oxygenase in solid
tumor.  Cancer Res 2003, 63:3567-3574.
15. Hirai K, Sasahira T, Ohmori H, Fujii K, Kuniyasu H: Inhibition of
heme oxygenase-1 by zinc protoporphyrin IX reduces tumor
growth of LL/2 lung cancer in C57BL mice.  Int J Cancer 2007,
120:500-505.
16. Fang J, Sawa T, Akaike T, Greish K, Maeda H: Enhancement of
chemotherapeutic response of tumor cells by a heme oxyge-
nase inhibitor, pegylated zinc protoporphyrin.  Int J Cancer
2004, 109:1-8.
17. Kim HR, Kim S, Kim EJ, Park JH, Yang SH, Jeong ET, Park C, Youn MJ,
So HS, Park R: Suppression of Nrf2-driven heme oxygenase-1
enhances the chemosensitivity of lung cancer A549 cells
toward cisplatin.  Lung Cancer 2007, 60:47-56.
18. Issat T, Nowis D, Legat M, Makowski M, Klejman MP, Urbanski J, Ski-
erski J, Koronkiewicz M, Stoklosa T, Brzezinska A, et al.: Potentiated
antitumor effects of the combination treatment with statins
and pamidronate in vitro and in vivo.  Int J Oncol 2007,
30:1413-1425.
19. Golab J, Nowis D, Skrzycki M, Czeczot H, Baranczyk-Kuzma A, Wilc-
zynski GM, Makowski M, Mroz P, Kozar K, Kaminski R, et al.: Anti-
tumor effects of photodynamic therapy are potentiated by 2-
methoxyestradiol. A superoxide dismutase inhibitor.  J Biol
Chem 2003, 278:407-414.
20. Doi K, Akaike T, Fujii S, Tanaka S, Ikebe N, Beppu T, Shibahara S,
Ogawa M, Maeda H: Induction of haem oxygenase-1 nitric
oxide and ischaemia in experimental solid tumours and
implications for tumour growth.  Brit J Cancer 1999,
80:1945-1954.
21. Hill M, Pereira V, Chauveau C, Zagani R, Remy S, Tesson L, Mazal D,
Ubillos L, Brion R, Asghar K, et al.: Heme oxygenase-1 inhibits rat
and human breast cancer cell proliferation: mutual cross
inhibition with indoleamine 2,3-dioxygenase.  Faseb J 2005,
19:1957-1968.
22. Yang G, Nguyen X, Ou J, Rekulapelli P, Stevenson DK, Dennery PA:
Unique effects of zinc protoporphyrin on HO-1 induction
and apoptosis.  Blood 2001, 97:1306-1313.
23. Sun MH, Pang JH, Chen SL, Kuo PC, Chen KJ, Kao LY, Wu JY, Lin KK,
Tsao YP: Photoreceptor Protection against Light Damage by
AAV-Mediated Overexpression of Heme Oxygenase-1.  Invest
Ophthalmol Vis Sci 2007, 48:5699-5707.
24. Vitek L, Schwertner HA: The heme catabolic pathway and its
protective effects on oxidative stress-mediated diseases.  Adv
Clin Chem 2007, 43:1-57.
25. Kim KM, Pae HO, Zheng M, Park R, Kim YM, Chung HT: Carbon
monoxide induces heme oxygenase-1 via activation of pro-
tein kinase R-like endoplasmic reticulum kinase and inhibits
endothelial cell apoptosis triggered by endoplasmic reticu-
lum stress.  Circ Res 2007, 101:919-927.
26. Sass G, Seyfried S, Parreira Soares M, Yamashita K, Kaczmarek E,
Neuhuber WL, Tiegs G: Cooperative effect of biliverdin and
carbon monoxide on survival of mice in immune-mediated
liver injury.  Hepatology 2004, 40:1128-1135.
27. Araujo JA, Meng L, Tward AD, Hancock WW, Zhai Y, Lee A, Ishikawa
K, Iyer S, Buelow R, Busuttil RW, et al.: Systemic rather than local
heme oxygenase-1 overexpression improves cardiac allo-
graft outcomes in a new transgenic mouse.  J Immunol 2003,
171:1572-1580.
28. Soares MP, Lin Y, Anrather J, Csizmadia E, Takigami K, Sato K, Grey
ST, Colvin RB, Choi AM, Poss KD, Bach FH: Expression of heme
oxygenase-1 can determine cardiac xenograft survival.
Nature Med 1998, 4:1073-1077.
29. Guo JS, Cho CH, Wang WP, Shen XZ, Cheng CL, Koo MW: Expres-
sion and activities of three inducible enzymes in the healing
of gastric ulcers in rats.  World J Gastroenterol 2003, 9:1767-1771.
30. Matsuoka Y, Masuda H, Yokoyama M, Kihara K: Protective effects
of heme oxygenase-1 against cyclophosphamide-induced
haemorrhagic cystitis in rats.  BJU Int 2007, 100:1402-1408.
31. Schaaf GJ, Maas RF, de Groene EM, Fink-Gremmels J: Management
of oxidative stress by heme oxygenase-1 in cisplatin-induced
toxicity in renal tubular cells.  Free Radic Res 2002,
36(8):835-843.
32. So HS, Kim HJ, Lee JH, Lee JH, Park SY, Park C, Kim YH, Kim JK, Lee
KM, Kim KS, et al.: Flunarizine induces Nrf2-mediated tran-
scriptional activation of heme oxygenase-1 in protection of
auditory cells from cisplatin.  Cell Death Differ 2006,
13:1763-1775.
33. Suliman HB, Carraway MS, Ali AS, Reynolds CM, Welty-Wolf KE,
Piantadosi CA: The CO/HO system reverses inhibition of
mitochondrial biogenesis and prevents murine doxorubicin
cardiomyopathy.  J Clin Invest 2007, 117:3730-3741.
34. Shiraishi F, Curtis LM, Truong L, Poss K, Visner GA, Madsen K, Nick
HS, Agarwal A: Heme oxygenase-1 gene ablation or expres-
sion modulates cisplatin-induced renal tubular apoptosis.  Am
J Physiol Renal Physiol 2000, 278(5):F726-736.
35. Tozer GM, Prise VE, Motterlini R, Poole BA, Wilson J, Chaplin DJ:
The comparative effects of the NOS inhibitor, Nomega-
nitro-L-arginine, and the haemoxygenase inhibitor, zinc pro-
toporphyrin IX, on tumour blood flow.  Int J Radiat Oncol Biol Phys
1998, 42:849-853.
36. Iyer AK, Greish K, Seki T, Okazaki S, Fang J, Takeshita K, Maeda H:
Polymeric micelles of zinc protoporphyrin for tumor tar-
geted delivery based on EPR effect and singlet oxygen gener-
ation.  J Drug Target 2007, 15:496-506.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/8/197/pre
pubPage 12 of 12
(page number not for citation purposes)
